bioMérieux Announces the Appointment of Stefan Willemsen as President and CEO of bioMérieux Inc.

He will lead all administrative, commercial and production operations of the bioMérieux Group in the recently created North and Latin America region. Mr. Willemsen will be headquartered at the company’s global BacT/ALERT® manufacturing and distribution site in Durham, NC. As a German national and attorney by training, he holds a Masters Degree in international commercial law from George Washington University in Washington D.C. and has been a member of the New York Bar since 1999.

Mr. Willemsen joined bioMérieux in 2010 after ten years in legal and business development roles at Roche Diagnostics. As General Counsel of bioMérieux he led all legal and intellectual property teams for the Group. In particular, as Corporate VP for business development Stefan Willemsen led a series of significant acquisitions and strategic alliances, including the recent strategic acquisition of BioFire Diagnostics in Salt Lake City. Willemsen was heavily involved in the negotiations with Kratos and the acquisition of the assets of Anagnostec in 2010, he also played an integral role in the long-term strategic collaboration with Shimadzu in 2011.

Mr. Willemsen’s contributions have supported the 510(k) de novo clearance for the VITEK® MS platform for rapid identification of a comprehensive menu of microorganisms and the recent addition to the bioMérieux portfolio: FilmArray® including FDA cleared multiplex panels for respiratory, sepsis and gastrointestinal infections.

“The nomination of Stefan Willemsen as President and CEO of bioMérieux Inc. is part of the new organization we are implementing to accelerate the operational development of our strategic plan and always better serve our customers,” said Alexandre Mérieux, bioMérieux Chief Executive Officer. “ I am convinced Stefan and his team will propel the development of bioMérieux in the Americas aligned with bioMérieux’s pioneering vision and dedication to public health.”

“I strongly believe in bioMérieux’s mission to advance public health by empowering clinical decisions and helping Pharma and the Food industry to supply safer products,” said Mr. Willemsen. “Our focus in the Americas will be to deliver innovative solutions and services to our customers, restore a satisfactory level of production and supply at our Durham site and drive sustained operational excellence at all our manufacturing facilities.”

Mr. Willemsen will relocate to Durham and will oversee all operational activities for all clinical and industrial business lines of bioMérieux in North and Latin America.

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors. In 2013, revenues reached €1.588 billion with 87% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux-usa.com

Contacts

Media Relations

bioMérieux
Allan Mohess
Tel: +1 919-479-3639
allan.mohess@bioMérieux.com

Baker & Yorke
Tim Baker
Tel: + 1 216-338-8086
tbaker@baker-yorke.com